Page last updated: 2024-08-21

quinazolines and Neuroendocrine Tumors

quinazolines has been researched along with Neuroendocrine Tumors in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M1
Chiu, CW; Hanahan, D; Nozawa, H1
Siu, LL1
Fujimoto, N; Fujiwara, K; Hamazaki, S; Kiura, K; Kozuki, T; Mizobuchi, K; Shiomi, K; Tabata, M; Tanimoto, M; Ueoka, H1
Ames, MM; Gilbert, JA; Lloyd, RV1

Reviews

1 review(s) available for quinazolines and Neuroendocrine Tumors

ArticleYear
[Targeted therapies, prognostic and predictive factors in endocrine oncology].
    Annales d'endocrinologie, 2013, Volume: 74 Suppl 1

    Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome

2013

Other Studies

4 other study(ies) available for quinazolines and Neuroendocrine Tumors

ArticleYear
Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-10, Volume: 28, Issue:29

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival; Clinical Trials, Phase II as Topic; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Immunosuppressive Agents; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Mice; Mice, Transgenic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Repressor Proteins; RNA Interference; Signal Transduction; Sirolimus; Survival Analysis; Survivin; TOR Serine-Threonine Kinases; Treatment Outcome

2010
Small tumors, intermediate models, big hopes.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-10, Volume: 28, Issue:29

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunosuppressive Agents; Intracellular Signaling Peptides and Proteins; Mice; Mice, Transgenic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome

2010
Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma.
    Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Quinazolines; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Failure; Treatment Outcome

2005
Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors.
    The New England journal of medicine, 2005, Jul-14, Volume: 353, Issue:2

    Topics: Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gastrointestinal Neoplasms; Gefitinib; Humans; Molecular Sequence Data; Mutation; Neuroendocrine Tumors; Pancreatic Neoplasms; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines

2005